BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 35237300)

  • 1. Identification of a Novel Immune-Related lncRNA CTD-2288O8.1 Regulating Cisplatin Resistance in Ovarian Cancer Based on Integrated Analysis.
    Liu T; Shen J; He Q; Xu S
    Front Genet; 2022; 13():814291. PubMed ID: 35237300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive Analyses Identify APOBEC3A as a Genomic Instability-Associated Immune Prognostic Biomarker in Ovarian Cancer.
    Xu F; Liu T; Zhou Z; Zou C; Xu S
    Front Immunol; 2021; 12():749369. PubMed ID: 34745121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Downregulation of LINC01508 contributes to cisplatin resistance in ovarian cancer via the regulation of the Hippo-YAP pathway.
    Xiao L; Shi XY; Li ZL; Li M; Zhang MM; Yan SJ; Wei ZL
    J Gynecol Oncol; 2021 Sep; 32(5):e77. PubMed ID: 34132072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel risk score system for assessment of ovarian cancer based on co-expression network analysis and expression level of five lncRNAs.
    Zhao Q; Fan C
    BMC Med Genet; 2019 Jun; 20(1):103. PubMed ID: 31182053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and validation of lncRNAs involved in m6A regulation for patients with ovarian cancer.
    Zheng J; Guo J; Cao B; Zhou Y; Tong J
    Cancer Cell Int; 2021 Jul; 21(1):363. PubMed ID: 34238292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A methylation- and immune-related lncRNA signature to predict ovarian cancer outcome and uncover mechanisms of chemoresistance.
    Chen L; Gao W; Lin L; Sha C; Li T; Chen Q; Wei H; Yang M; Xing J; Zhang M; Zhao S; Xu W; Li Y; Long L; Zhu X
    J Ovarian Res; 2023 Sep; 16(1):186. PubMed ID: 37674251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-149-3p promotes the cisplatin resistance and EMT in ovarian cancer through downregulating TIMP2 and CDKN1A.
    Wang J; Liu L
    J Ovarian Res; 2021 Nov; 14(1):165. PubMed ID: 34798882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of MEG8/miR-378d/SOBP axis as a novel regulatory network and associated with immune infiltrates in ovarian carcinoma by integrated bioinformatics analysis.
    Lei J; He ZY; Wang J; Hu M; Zhou P; Lian CL; Hua L; Wu SG; Zhou J
    Cancer Med; 2021 Apr; 10(8):2924-2939. PubMed ID: 33742531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CircITGB6 promotes ovarian cancer cisplatin resistance by resetting tumor-associated macrophage polarization toward the M2 phenotype.
    Li H; Luo F; Jiang X; Zhang W; Xiang T; Pan Q; Cai L; Zhao J; Weng D; Li Y; Dai Y; Sun F; Yang C; Huang Y; Yang J; Tang Y; Han Y; He M; Zhang Y; Song L; Xia JC
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35277458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Four Prognosis-Associated lncRNAs Serve as Biomarkers in Ovarian Cancer.
    Zheng J; Guo J; Zhang H; Cao B; Xu G; Zhang Z; Tong J
    Front Genet; 2021; 12():672674. PubMed ID: 34367239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long Noncoding RNA LINC01125 Enhances Cisplatin Sensitivity of Ovarian Cancer via miR-1972.
    Guo J; Pan H
    Med Sci Monit; 2019 Dec; 25():9844-9854. PubMed ID: 31865363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin-like growth factor 2 mRNA-binding protein 2 is a therapeutic target in ovarian cancer.
    Yuan J; Li X; Wang F; Liu H; Guan W; Xu G
    Exp Biol Med (Maywood); 2023 Dec; 248(23):2198-2209. PubMed ID: 38084732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of EMP1 as a critical gene for cisplatin resistance in ovarian cancer by using integrated bioinformatics analysis.
    Zeng Q; Yi C; Lu J; Wang X; Chen K; Hong L
    Cancer Med; 2023 Apr; 12(7):9024-9040. PubMed ID: 36708070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive analysis of competitive endogenous RNAs networks reveals potential prognostic biomarkers associated with epithelial ovarian cancer.
    Wu W; Gao C; Chen L; Zhang D; Guo S
    Oncol Lett; 2021 Dec; 22(6):843. PubMed ID: 34777587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Potential Immune-Related Long Non-coding RNA Prognostic Signature for Ovarian Cancer.
    Pan X; Bi F
    Front Genet; 2021; 12():694009. PubMed ID: 34367253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DMBT1 suppresses cell proliferation, migration and invasion in ovarian cancer and enhances sensitivity to cisplatin through galectin-3/PI3k/Akt pathway.
    Ma N; Zhao Y
    Cell Biochem Funct; 2020 Aug; 38(6):801-809. PubMed ID: 32424818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Excavating novel diagnostic and prognostic long non-coding RNAs (lncRNAs) for head and neck squamous cell carcinoma: an integrated bioinformatics analysis of competing endogenous RNAs (ceRNAs) and gene co-expression networks.
    Yang L; Lu P; Yang X; Li K; Chen X; Qu S
    Bioengineered; 2021 Dec; 12(2):12821-12838. PubMed ID: 34898376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Construction of Competitive Endogenous RNA Network and Verification of 3-Key LncRNA Signature Associated With Distant Metastasis and Poor Prognosis in Patients With Clear Cell Renal Cell Carcinoma.
    Su Y; Zhang T; Tang J; Zhang L; Fan S; Zhou J; Liang C
    Front Oncol; 2021; 11():640150. PubMed ID: 33869028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Construction of a Ferroptosis-Related Nine-lncRNA Signature for Predicting Prognosis and Immune Response in Hepatocellular Carcinoma.
    Xu Z; Peng B; Liang Q; Chen X; Cai Y; Zeng S; Gao K; Wang X; Yi Q; Gong Z; Yan Y
    Front Immunol; 2021; 12():719175. PubMed ID: 34603293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CTD-2020K17.1, a Novel Long Non-Coding RNA, Promotes Migration, Invasion, and Proliferation of Serous Ovarian Cancer Cells In Vitro.
    Zhu L; Guo Q; Lu X; Zhao J; Shi J; Wang Z; Zhou X
    Med Sci Monit; 2018 Mar; 24():1329-1339. PubMed ID: 29504606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.